GlobeStar Therapeutics(OTC) SOAN

Market CapN/A

Since IPO (2016)-100%

5 Year-100%

1 Year+0%

1 Month+0%

N/A

GlobeStar Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-08-28

GlobeStar Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-08-18
1 month	+0%	USD 0.00	2026-07-22
3 month	+0%	USD 0.00	2026-05-28
Year to date	+0%	USD 0.00	2025-12-31
1 year	+0%	USD 0.00	2025-08-25
3 year	-99.96%	USD 0.00	2023-08-29
5 year	-100%	USD 0.03	2021-08-27
Since inception	-100%	USD 0.11	2016-06-23

GlobeStar Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.08

Net Income (TTM)

-$5.54M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

SOAN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GlobeStar Therapeutics

GlobeStar Therapeutics Corporation is a clinical-stage biopharmaceutical firm focused on developing proprietary drug formulations for multiple sclerosis and other neurodegenerative disorders. Established in 2016 and rebranded in 2021, the company operates from Richland, Washington.

Products and Services

Innovative drug formulations targeting multiple sclerosis
Research and development in neurodegenerative disorders
Clinical trials to validate therapeutic efficacy

Growth Outlook

Potential market expansion in neurodegenerative therapies
Increased focus on clinical trials to drive product development
Strategic partnerships may enhance research capabilities

Financial Highlights

Recent quarterly net income of -198,000, reflecting ongoing operational costs
Trailing twelve months show a consistent negative net income trend
Cash and short-term investments totaled 41, indicating liquidity challenges

GlobeStar Therapeutics Corporation is positioned in a promising sector with significant growth potential. The focus on innovative treatments for debilitating conditions like multiple sclerosis aligns with increasing healthcare demands. However, the financial data indicates ongoing challenges, particularly in achieving profitability. The company’s ability to navigate these challenges while advancing its clinical programs will be crucial for future success. Investors may find interest in the potential for strategic partnerships and market expansion as the company continues its development efforts.

AI Generated • Sep 1, 2026

Industry

Biotechnology

Sector

Health Care

CEO

James C. Katzaroff

Website

globestarthera.com

Headquarters

Houston, TX, US

SOAN Financials

Key Financial Metrics (TTM)

Gross Margin

-48837.66%

Operating Margin

-394377.92%

Net Income Margin

-703546.75%

Return on Equity

80.58%

Return on Capital

N/A

Return on Assets

-602.51%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$2.45K

Operating Income

-$5.01M

EBITDA

-$5.28M

Operating Cash Flow

$26.89K

Capital Expenditure

$1.78K

Free Cash Flow

$28.68K

Cash & ST Invst.

$20.48K

Total Debt

$59.65K

GlobeStar Therapeutics Performance Analysis

GlobeStar Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-09-30	USD 0	N/A
2022	2022-09-30	USD 0	N/A
2023	2023-09-30	USD 0	N/A

GlobeStar Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2020-09-30	N/A
Q1	2020-12-31	-100.0%
Q2	2021-03-31	N/A
Q3	2021-06-30	N/A

GlobeStar Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-09-30	USD -0.02	N/A
2022	2022-09-30	USD -0.00	-88.2%
2023	2023-09-30	USD -0.00	0.0%

GlobeStar Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2020-09-30	99.7%
Q1	2020-12-31	-41069.2%
Q2	2021-03-31	-375.0%
Q3	2021-06-30	-405.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2021YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$4.52M

-5035.5%

EBITDA

-$4.48M

-9158.6%

Quarterly Fundamentals

Name

Q3 2021YOY CHG

Total Cash

$20.48K

-59.3%

Total Debt

$59.65K

-65.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

-100.0%

Long Term Debt

$0.00

N/A

Short Term Debt

$59.65K

-65.5%

Return on Assets

-6.03%

N/A

Return on Invested Capital

46.07%

N/A

Free Cash Flow

-$138.41K

-265.1%

Operating Cash Flow

-$138.41K

-267.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IGXTIntelGenx Technologies Corp.

IGXTIntelGenx Technologies Corp.$0.17+0.00%

IBXNFIBEX Technologies Inc.

IBXNFIBEX Technologies Inc.$1.00-6.54%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$71.92+0.00%

WETOWetour Robotics

WETOWetour Robotics$5.48-0.04%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$44.67+0.02%

INTCIntel

INTCIntel$89.51+0.00%

NVDANvidia

NVDANvidia$220.78+0.01%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

Questions About SOAN

What is the current price of GlobeStar Therapeutics?

GlobeStar Therapeutics is trading at N/A per share.

What is the 52-week range for GlobeStar Therapeutics?

Over the past 52 weeks, GlobeStar Therapeutics has traded between N/A and N/A.

How much debt does GlobeStar Therapeutics have?

As of the most recent reporting period, GlobeStar Therapeutics reported total debt of $359.71K.

How much cash does GlobeStar Therapeutics have on hand?

GlobeStar Therapeutics reported $0.00 in cash and cash equivalents in its most recent financial results.

What is GlobeStar Therapeutics’s dividend yield?

GlobeStar Therapeutics does not currently have a dividend yield.

GlobeStar Therapeutics(OTC) SOAN

GlobeStar Therapeutics Financials at a Glance

SOAN News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About GlobeStar Therapeutics

SOAN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

GlobeStar Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About SOAN

What is the current price of GlobeStar Therapeutics?

What is the 52-week range for GlobeStar Therapeutics?

How much debt does GlobeStar Therapeutics have?

How much cash does GlobeStar Therapeutics have on hand?

What is GlobeStar Therapeutics’s dividend yield?

Premium Investing Services